Paradigm Health has simultaneously activated its Study Conduct platform for Phase 1b and Phase 2 clinical trials with two major pharma companies: Amgen and AstraZeneca.1 The concurrent go-live concentrates operational risk at the worst possible moment—before the system has accumulated a track record.
Study Conduct provides real-time regulatory review of clinical trial data, ingesting electronic health records and applying automated classification across live trial data streams. Each component of that chain carries a distinct failure mode.
EHR integration outages present the most immediate threat. Disconnections between hospital systems and the platform generate data gaps. In early-phase trials, regulators treat unexplained data gaps as missing data—a finding that can invalidate safety signals or efficacy endpoints entirely.
Algorithmic misclassification is a second vector. Automated systems that incorrectly categorize adverse events or patient eligibility can distort outcomes without triggering immediate alerts. Phase 1b and Phase 2 trials use small patient populations. A single misclassification carries outsized statistical weight.
Data ingestion errors compound both risks. If raw data fails to load correctly at the source, all downstream analysis reflects corrupted inputs. Post-hoc reconciliation is difficult and may not satisfy FDA data integrity standards.
Running Amgen and AstraZeneca trials in parallel amplifies the exposure significantly.1 Errors affecting both sponsors concurrently would open parallel liability tracks and draw simultaneous regulatory scrutiny—a combination that smaller platforms have historically struggled to manage.
The FDA relationship adds a second layer of risk. Real-time regulatory review is Paradigm Health's core value proposition. If early operational failures degrade data quality, regulators may reassess whether the platform meets oversight standards—potentially slowing broader adoption of the technology itself.
EHR integration failures have derailed multiple clinical trial platforms before commercial scale. Paradigm Health's launch window—high-stakes, multi-sponsor, with live regulatory data—leaves limited margin for the operational errors that are common in early deployment phases.
How the company manages this period will determine whether Study Conduct builds durable trust with pharma partners and the FDA, or faces a credibility crisis before the platform reaches scale.
Sources:
1 Paradigm Health operational risk assessment, April 30, 2026